DE602007013294D1 - Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)chinolin - Google Patents

Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)chinolin

Info

Publication number
DE602007013294D1
DE602007013294D1 DE602007013294T DE602007013294T DE602007013294D1 DE 602007013294 D1 DE602007013294 D1 DE 602007013294D1 DE 602007013294 T DE602007013294 T DE 602007013294T DE 602007013294 T DE602007013294 T DE 602007013294T DE 602007013294 D1 DE602007013294 D1 DE 602007013294D1
Authority
DE
Germany
Prior art keywords
methyl
chinoline
pyrazol
phenoxy
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013294T
Other languages
German (de)
English (en)
Inventor
Patrick Robert Vorhoest
Caroline Proulx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39321475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007013294(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602007013294D1 publication Critical patent/DE602007013294D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602007013294T 2006-12-21 2007-12-03 Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)chinolin Active DE602007013294D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87126006P 2006-12-21 2006-12-21
PCT/IB2007/003819 WO2008084299A1 (en) 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Publications (1)

Publication Number Publication Date
DE602007013294D1 true DE602007013294D1 (de) 2011-04-28

Family

ID=39321475

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013294T Active DE602007013294D1 (de) 2006-12-21 2007-12-03 Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)chinolin

Country Status (24)

Country Link
US (1) US8283471B2 (enExample)
EP (1) EP2125786B1 (enExample)
JP (1) JP5254602B2 (enExample)
KR (2) KR20090092338A (enExample)
CN (1) CN101611029B (enExample)
AR (1) AR064417A1 (enExample)
AT (1) ATE502028T1 (enExample)
AU (1) AU2007343135B2 (enExample)
BR (1) BRPI0720936A2 (enExample)
CA (1) CA2673435C (enExample)
CY (1) CY1111919T1 (enExample)
DE (1) DE602007013294D1 (enExample)
DK (1) DK2125786T3 (enExample)
ES (1) ES2360014T3 (enExample)
IL (1) IL199389A (enExample)
MX (1) MX2009006528A (enExample)
NZ (1) NZ577716A (enExample)
PL (1) PL2125786T3 (enExample)
PT (1) PT2125786E (enExample)
RU (1) RU2430918C2 (enExample)
SI (1) SI2125786T1 (enExample)
TW (1) TWI359660B (enExample)
WO (1) WO2008084299A1 (enExample)
ZA (1) ZA200904230B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120214842A1 (en) * 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd benzothiophene derivative
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR102233916B1 (ko) * 2019-05-28 2021-03-30 주식회사 엘지생활건강 Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105551A1 (de) * 1991-02-22 1992-08-27 Bayer Ag 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EA011451B1 (ru) * 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
CA2536073A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
WO2006072828A2 (en) * 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2006078825A2 (en) 2005-01-21 2006-07-27 Cabot Corporation Processes for forming nanoparticles
AU2006329849A1 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound

Also Published As

Publication number Publication date
CA2673435C (en) 2012-10-09
KR20090092338A (ko) 2009-08-31
BRPI0720936A2 (pt) 2014-03-11
AR064417A1 (es) 2009-04-01
ATE502028T1 (de) 2011-04-15
JP5254602B2 (ja) 2013-08-07
AU2007343135A1 (en) 2008-07-17
IL199389A (en) 2014-01-30
CN101611029A (zh) 2009-12-23
HK1134670A1 (en) 2010-05-07
EP2125786B1 (en) 2011-03-16
PL2125786T3 (pl) 2011-07-29
EP2125786A1 (en) 2009-12-02
SI2125786T1 (sl) 2011-05-31
TWI359660B (en) 2012-03-11
MX2009006528A (es) 2009-06-26
WO2008084299A1 (en) 2008-07-17
NZ577716A (en) 2012-10-26
PT2125786E (pt) 2011-04-21
US20100063089A1 (en) 2010-03-11
CY1111919T1 (el) 2015-11-04
ES2360014T3 (es) 2011-05-31
RU2009123347A (ru) 2011-01-27
ZA200904230B (en) 2010-04-28
TW200833337A (en) 2008-08-16
AU2007343135B2 (en) 2013-03-21
JP2008208114A (ja) 2008-09-11
RU2430918C2 (ru) 2011-10-10
CA2673435A1 (en) 2008-07-17
DK2125786T3 (da) 2011-05-09
KR20120043775A (ko) 2012-05-04
CN101611029B (zh) 2014-09-10
US8283471B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
IL269977B (en) 2-(1-isopropyl-pyrazol-5-yl)-3-(hydroxy/chloro)methyl-pyridine compounds
ATE502013T1 (de) Pyridonderivate als inhibitoren von p38a-mapk
ATE502028T1 (de) Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)- 1h-pyrazol-3-yl)phenoxy)methyl)chinolin
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
ATE516272T1 (de) 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
PL2625175T3 (pl) Krystaliczny ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropirydyn-4-ylo)etoksy)-1H-indazol-3-ilo)winylo)-1H-pirazol-1-ilo)etanol i jego zastosowanie jako inhibitora FGFR
DK3170818T3 (da) Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
NZ627586A (en) Pyridone derivatives
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
CY2017038I2 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
IL233830B (en) Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, processes for producing same and uses thereof
EP1900732A4 (en) NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
DK2049487T3 (da) Fremgangsmåde til fremstilling af 2-substituerede 5-(1-alkylthio)alkylpyridiner
ATE475649T1 (de) Pyridincarboxamide als 11-beta-hsd1-inhibitoren
DK2182950T3 (da) Anvendelse af 4-(pyrrolidin-1-yl)quinolinforbindelser til at dræbe klinisk latente mikroorganismer
DE60320529D1 (de) Chinolinderivate als npy antagonisten
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DE602006010870D1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
LT3921030T (lt) 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
ATE486062T1 (de) 4-(4-trifluormethyl-3-thiobenzoyl)pyrazole und ihre verwendung als herbizide
ATE499356T1 (de) 6-(pyridinyl)-4-pyrimidonderivate als inhibitoren der tau-proteinkinase-1
DK2358674T3 (da) Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser